The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 0, 1 Feinberg, 1983, Hypomethylation distinguishes genes of some human cancers from their normal counterparts, Nature, 301, 89, 10.1038/301089a0 Waddington, 2012, The epigenotype, Int J Epidemiol, 41, 10, 10.1093/ije/dyr184 Lee, 2022, Cancer epigenetics: past, present and future, Semin Cancer Biol, 83, 4, 10.1016/j.semcancer.2021.03.025 Zhao, 2021, The language of chromatin modification in human cancers, Nat Rev Cancer, 21, 413, 10.1038/s41568-021-00357-x Ribeiro-Silva, 2019, SWI/SNF: complex complexes in genome stability and cancer, DNA Repair, 77, 87, 10.1016/j.dnarep.2019.03.007 Lowe, 2019, Histone H3 mutations: an updated view of their role in chromatin deregulation and cancer, Cancers (Basel), 11, 660, 10.3390/cancers11050660 Yang, 2021, Role of epigenetic regulation in plasticity of tumor immune microenvironment, Front Immunol, 12 Zhao, 2019, Epigenetic modifications of histones in cancer, Genome Biol, 20, 1, 10.1186/s13059-019-1870-5 Chan, 2020, Nothing is yet set in (hi)stone: novel post-translational modifications regulating chromatin function, Trends Biochem Sci, 45, 829, 10.1016/j.tibs.2020.05.009 Bannister, 2011, Regulation of chromatin by histone modifications, Cell Res, 21, 381, 10.1038/cr.2011.22 Saleh, 2020, Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression, Front Immunol, 11, 1469, 10.3389/fimmu.2020.01469 Xhemalce, 2011, Histone modifications Dawson, 2012, Cancer epigenetics: from mechanism to therapy, Cell, 150, 12, 10.1016/j.cell.2012.06.013 Sharma, 2021, Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers, Cancer Investig, 39, 257, 10.1080/07357907.2021.1872593 Mohammad, 2017, Oncohistones: drivers of pediatric cancers, Genes Dev, 31, 2313, 10.1101/gad.309013.117 Choudhary, 2009, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science, 325, 834, 10.1126/science.1175371 Martin, 2021, Transcription shapes genome-wide histone acetylation patterns, Nat Commun, 12, 210, 10.1038/s41467-020-20543-z Kori, 2017, Proteome-wide acetylation dynamics in human cells, Sci Rep, 7, 10296, 10.1038/s41598-017-09918-3 Cohen, 2011, Histone modifiers in cancer: friends or foes?, Genes Cancer, 2, 631, 10.1177/1947601911417176 Sugiura, 2021, Epigenetic modifications in prostate cancer, Int J Urol, 28, 140, 10.1111/iju.14406 Zhan, 2020, Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation, J Exp Med, 4, 10.1084/jem.20191340 Jones, 2016, Targeting the cancer epigenome for therapy, Nat Rev Genet, 17, 630, 10.1038/nrg.2016.93 Villanueva, 2020, The contribution of epigenetics to cancer immunotherapy, Trends Immunol, 41, 676, 10.1016/j.it.2020.06.002 Surapaneni, 2020, MicroRNA-941 regulates the proliferation of breast cancer cells by altering histone H3 Ser 10 phosphorylation, Sci Rep, 10, 17954, 10.1038/s41598-020-74847-7 Komar, 2020, Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy, Clin Epigenetics, 12, 147, 10.1186/s13148-020-00941-2 Ju, 2017, NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression, Nat Commun, 8, 928, 10.1038/s41467-017-00988-5 Martire, 2019, Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation, Nat Genet, 51, 941, 10.1038/s41588-019-0428-5 Mattiroli, 2021, Histone ubiquitination: an integrative signaling platform in genome stability, Trends Genet, 37, 566, 10.1016/j.tig.2020.12.005 van Mierlo, 2019, The complexity of PRC2 subcomplexes, Trends Cell Biol, 29, 660, 10.1016/j.tcb.2019.05.004 Zylicz, 2019, The implication of early chromatin changes in X chromosome inactivation, Cell, 176, 182, 10.1016/j.cell.2018.11.041 Hu, 2012, CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis, Cancer Cell, 22, 781, 10.1016/j.ccr.2012.10.024 Tamburri, 2022, Polycomb-dependent histone H2A ubiquitination links developmental disorders with cancer, Trends Genet, 38, 333, 10.1016/j.tig.2021.07.011 Kim, 2009, RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells, Cell, 137, 459, 10.1016/j.cell.2009.02.027 Adhikary, 2019, Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor, Nat Commun, 10, 1398, 10.1038/s41467-019-08986-5 Shilatifard, 2006, Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression, Annu Rev Biochem, 75, 243, 10.1146/annurev.biochem.75.103004.142422 Serrano-Quilez, 2020, Sharing marks: H3K4 methylation and H2B ubiquitination as features of meiotic recombination and transcription, Int J Mol Sci, 21, 4510, 10.3390/ijms21124510 Wang, 2018, Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy, Nat Med, 24, 758, 10.1038/s41591-018-0034-6 Fang, 2021, Histone crotonylation promotes mesoendodermal commitment of human embryonic stem cells, Cell Stem Cell, 28, 748, 10.1016/j.stem.2020.12.009 Li, 2016, Molecular coupling of histone crotonylation and active transcription by AF9 YEATS domain, Mol Cell, 62, 181, 10.1016/j.molcel.2016.03.028 Goudarzi, 2016, Dynamic competing histone H4 K5K8 acetylation and butyrylation are hallmarks of highly active gene promoters, Mol Cell, 62, 169, 10.1016/j.molcel.2016.03.014 Zhu, 2021, Identification of lysine isobutyrylation as a new histone modification mark, Nucleic Acids Res, 49, 177, 10.1093/nar/gkaa1176 Yan, 2020, Deficient histone H3 propionylation by BRPF1-KAT6 complexes in neurodevelopmental disorders and cancer, Sci Adv, 6, eaax0021, 10.1126/sciadv.aax0021 Zhang, 2011, Identification of lysine succinylation as a new post-translational modification, Nat Chem Biol, 7, 58, 10.1038/nchembio.495 Sreedhar, 2020, Enzymatic and metabolic regulation of lysine succinylation, Genes Dis, 7, 166, 10.1016/j.gendis.2019.09.011 Zhang, 2021, Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors, Cancer Biol Med, 19, 133, 10.20892/j.issn.2095-3941.2021.0533 Jing, 2022, Roles of negatively charged histone lysine acylations in regulating nucleosome structure and dynamics, Front Mol Biosci, 9, 10.3389/fmolb.2022.899013 Liberti, 2020, Histone lactylation: a new role for glucose metabolism, Trends Biochem Sci, 45, 179, 10.1016/j.tibs.2019.12.004 Zhang, 2019, Metabolic regulation of gene expression by histone lactylation, Nature, 574, 575, 10.1038/s41586-019-1678-1 Ryu, 2021, Histone sumoylation and chromatin dynamics, Nucleic Acids Res, 49, 6043, 10.1093/nar/gkab280 Leonen, 2021, Sumoylation of the human histone H4 tail inhibits p300-mediated transcription by RNA polymerase II in cellular extracts, Elife, 10, e67952, 10.7554/eLife.67952 Zheng, 2021, Targeting neddylation E2s: a novel therapeutic strategy in cancer, J Hematol Oncol, 14, 57, 10.1186/s13045-021-01070-w Shi, 2020, Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study, Am J Cancer Res, 10, 953 Chen, 2020, Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27(Kip1), Exp Cell Res, 392, 10.1016/j.yexcr.2020.112038 Ferris, 2020, Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer, Cell Death Discov, 6, 61, 10.1038/s41420-020-00296-w Messner, 2011, Histone ADP-ribosylation in DNA repair, replication and transcription, Trends Cell Biol, 21, 534, 10.1016/j.tcb.2011.06.001 Chen, 2021, ADP-ribosylation of histone variant H2AX promotes base excision repair, EMBO J, 40, 10.15252/embj.2020104542 Chen, 2013, TET2 promotes histone O-GlcNAcylation during gene transcription, Nature, 493, 561, 10.1038/nature11742 Xu, 2014, AMPK regulates histone H2B O-GlcNAcylation, Nucleic Acids Res, 42, 5594, 10.1093/nar/gku236 Jiang, 2007, N-formylation of lysine in histone proteins as a secondary modification arising from oxidative DNA damage, Proc Natl Acad Sci U S A, 104, 60, 10.1073/pnas.0606775103 Weinberg, 2019, The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape, Nature, 573, 281, 10.1038/s41586-019-1534-3 Xu, 2020, DNMT3A reads and connects histone H3K36me2 to DNA methylation, Protein Cell, 11, 150, 10.1007/s13238-019-00672-y Dukatz, 2019, H3K36me2/3 binding and DNA binding of the DNA methyltransferase DNMT3A PWWP domain both contribute to its chromatin interaction, J Mol Biol, 431, 5063, 10.1016/j.jmb.2019.09.006 Baubec, 2015, Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation, Nature, 520, 243, 10.1038/nature14176 Cui, 2018, DNA methyltransferase 3A isoform b contributes to repressing E-cadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer, Oncogene, 37, 4358, 10.1038/s41388-018-0285-1 Wu, 2005, Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis, Nature, 438, 981, 10.1038/nature04225 Na, 2022, KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming, Nat Cancer, 3, 753, 10.1038/s43018-022-00361-6 Grosselin, 2019, High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer, Nat Genet, 51, 1060, 10.1038/s41588-019-0424-9 Hsu, 2018, STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion, Nat Commun, 9, 1908, 10.1038/s41467-018-04313-6 Darvin, 2019, PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications, J Oncol, 2019, 10.1155/2019/3958908 Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 Leslie, 2019, Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes, Nat Commun, 10, 4192, 10.1038/s41467-019-12222-5 de Nigris, 2021, Clinical efficiency of epigenetic drugs therapy in bone malignancies, Bone, 143, 10.1016/j.bone.2020.115605 Xie, 2022, HDAC2- and EZH2-mediated histone modifications induce PDK1 expression through miR-148a downregulation in breast cancer progression and adriamycin resistance, Cancers (Basel), 14, 3600, 10.3390/cancers14153600 Zhang, 2018, Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1alpha and APC2 gene expression in non-small cell lung cancer, Mol Cancer, 17, 153, 10.1186/s12943-018-0896-8 Rowbotham, 2018, H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression, Nat Commun, 9, 4559, 10.1038/s41467-018-07077-1 Wu, 2018, In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis, Proc Natl Acad Sci U S A, 115, E3978, 10.1073/pnas.1716589115 Burr, 2019, An evolutionarily conserved function of polycomb silences the MHC Class I antigen presentation pathway and enables immune evasion in cancer, Cancer Cell, 36, 385, 10.1016/j.ccell.2019.08.008 Qiu, 2019, CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter, Theranostics, 9, 4717, 10.7150/thno.33680 LaFave, 2015, Loss of BAP1 function leads to EZH2-dependent transformation, Nat Med, 21, 1344, 10.1038/nm.3947 Ezponda, 2017, UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition, Cell Rep, 21, 628, 10.1016/j.celrep.2017.09.078 Wang, 2009, LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer, Cell, 138, 660, 10.1016/j.cell.2009.05.050 Lu, 2018, ORY-1001 suppresses cell growth and induces apoptosis in lung cancer through triggering HK2 mediated Warburg effect, Front Pharmacol, 9, 1411, 10.3389/fphar.2018.01411 Bauer, 2019, Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC, J Thorac Oncol, 14, 1828, 10.1016/j.jtho.2019.06.021 Colao, 2020, Clinical epigenetics of neuroendocrine tumors: the road ahead, Front Endocrinol, 11, 10.3389/fendo.2020.604341 Ashktorab, 2009, Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma, Dig Dis Sci, 54, 2109, 10.1007/s10620-008-0601-7 Nakazawa, 2012, Global histone modification of histone H3 in colorectal cancer and its precursor lesions, Hum Pathol, 43, 834, 10.1016/j.humpath.2011.07.009 Karczmarski, 2014, Hitone H3 lysine 27 acetylation is altered in colon cancer, Clin Proteom, 11, 24, 10.1186/1559-0275-11-24 Tamagawa, 2012, The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer, Oncol Rep, 27, 637 Yokoyama, 2013, Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo, Cancer Sci, 104, 889, 10.1111/cas.12166 Benard, 2014, Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer, BMC Cancer, 14, 531, 10.1186/1471-2407-14-531 Gezer, 2013, Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer, Tumour Biol, 34, 329, 10.1007/s13277-012-0554-5 Gezer, 2015, Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer, Int J Mol Sci, 16, 29654, 10.3390/ijms161226180 Jung, 2020, Epigenetics of colorectal cancer: biomarker and therapeutic potential, Nat Rev Gastroenterol Hepatol, 17, 111, 10.1038/s41575-019-0230-y Monga, 2020, Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis, Sci Rep, 10, 6649, 10.1038/s41598-020-62845-8 Ge, 2020, Epigenetic modulations and lineage plasticity in advanced prostate cancer, Ann Oncol, 31, 470, 10.1016/j.annonc.2020.02.002 Metzger, 2019, KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells, Nat Struct Mol Biol, 26, 361, 10.1038/s41594-019-0219-9 Vatapalli, 2020, Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer, Nat Commun, 11, 4153, 10.1038/s41467-020-18013-7 Cai, 2014, Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity, Cell Rep, 9, 1618, 10.1016/j.celrep.2014.11.008 Fan, 2018, Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells, Proc Natl Acad Sci U S A, 115, E4584, 10.1073/pnas.1802415115 Zhou, 2022, RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression, Cell Death Dis, 13, 352, 10.1038/s41419-022-04787-9 Morishita, 2014, In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L, BMC Struct Biol, 14, 25 Kim, 2006, Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity, Biochem Biophys Res Commun, 345, 318, 10.1016/j.bbrc.2006.04.095 Kang, 2009, The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription, FEBS Lett, 583, 1880, 10.1016/j.febslet.2009.05.038 Yousefi, 2019, Epigenetic changes in gastric cancer induction by Helicobacter pylori, J Cell Physiol, 234, 21770, 10.1002/jcp.28925 Rivas-Ortiz, 2017, Genetic alterations in gastric cancer associated with helicobacter pylori infection, Front Med, 4, 47, 10.3389/fmed.2017.00047 Yang, 2018, Helicobacter pylori infection-induced H3Ser10 phosphorylation in stepwise gastric carcinogenesis and its clinical implications, Helicobacter, 23, e12486, 10.1111/hel.12486 Pathak, 2006, TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages, J Immunol, 177, 7950, 10.4049/jimmunol.177.11.7950 Fehri, 2009, Helicobacter pylori-induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation, Epigenetics, 4, 577, 10.4161/epi.4.8.10217 Xia, 2008, Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation, Biochem Biophys Res Commun, 369, 526, 10.1016/j.bbrc.2008.02.073 Mitani, 2005, Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma, J Pathol, 205, 65, 10.1002/path.1684 Han, 2016, JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression, Oncotarget, 7, 38626, 10.18632/oncotarget.9573 Park, 2008, The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma, Ann Surg Oncol, 15, 1968, 10.1245/s10434-008-9927-9 Hatakeyama, 2004, Oncogenic mechanisms of the Helicobacter pylori CagA protein, Nat Rev Cancer, 4, 688, 10.1038/nrc1433 Hayashi, 2013, CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis, Gut, 62, 1536, 10.1136/gutjnl-2011-301625 Hamdane, 2019, HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response, Gastroenterology, 156, 2313, 10.1053/j.gastro.2019.02.038 Jiang, 2020, lncRNA PVT1 promotes hepatitis B viruspositive liver cancer progression by disturbing histone methylation on the cMyc promoter, Oncol Rep, 43, 718 Han, 2018, The epigenetic regulation of HCC metastasis, Int J Mol Sci, 19, 3978, 10.3390/ijms19123978 Wei, 2017, Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3, J Hepatol, 67, 758, 10.1016/j.jhep.2017.05.015 Tang, 2015, JARID1B promotes metastasis and epithelial-mesenchymal transsition via PTEN/AKT signaling in hepatocellular carcinoma cells, Oncotarget, 6, 12723, 10.18632/oncotarget.3713 Chen, 2017, KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells, Oncotarget, 8, 17712, 10.18632/oncotarget.10832 Ji, 2015, Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression, BMC Cancer, 15, 801, 10.1186/s12885-015-1798-4 Zhang, 2018, Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma, BMC Cancer, 18, 539, 10.1186/s12885-018-4464-9 Wong, 2016, Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis, Hepatology, 63, 474, 10.1002/hep.28304 Liu, 2013, Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification, Cancer Lett, 339, 60, 10.1016/j.canlet.2013.07.022 Zhang, 2022, Targeting mTORC2/HDAC3 inhibits stemness of liver cancer cells against glutamine starvation, Adv Sci (Weinh), 9 Ji, 2019, HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition, Cancer Res, 79, 3676, 10.1158/0008-5472.CAN-18-3767 Hu, 2016, Epigenetics of hematopoiesis and hematological malignancies, Genes Dev, 30, 2021, 10.1101/gad.284109.116 van Dijk, 2018, Histone modification patterns using RPPA-based profiling predict outcome in acute myeloid leukemia patients, Proteomics, 18, 10.1002/pmic.201700379 Li, 2018, Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia, J Cancer Res Clin Oncol, 144, 1065, 10.1007/s00432-018-2631-7 van Dijk, 2020, Loss of H3K27 methylation identifies poor outcome in adult-onset acute myeloid leukemia, Blood, 136, 24, 10.1182/blood-2020-139387 Gollner, 2017, Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia, Nat Med, 23, 69, 10.1038/nm.4247 Rabello Ddo, 2015, Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia, Blood Cells Mol Dis, 54, 97, 10.1016/j.bcmd.2014.07.013 Chartomatsidou, 2019, Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia, Blood Adv, 3, 1891, 10.1182/bloodadvances.2018030262 Dhall, 2019, Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia, Front Oncol, 9, 432, 10.3389/fonc.2019.00432 Huang, 2021, CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis, Signal Transduct Target Ther, 6, 10, 10.1038/s41392-020-00437-8 Ortega-Molina, 2015, The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development, Nat Med, 21, 1199, 10.1038/nm.3943 Zhang, 2015, Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis, Nat Med, 21, 1190, 10.1038/nm.3940 Morin, 2011, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, 476, 298, 10.1038/nature10351 Ying, 2013, MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma, Nat Immunol, 14, 1084, 10.1038/ni.2688 Brescia, 2018, MEF2B instructs germinal center development and acts as an oncogene in B cell lymphomagenesis, Cancer Cell, 34, 453, 10.1016/j.ccell.2018.08.006 Zhang, 2019, Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas, Int J Med Sci, 16, 424, 10.7150/ijms.30154 Keats, 2003, In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression, Blood, 101, 1520, 10.1182/blood-2002-06-1675 Santra, 2003, A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Blood, 101, 2374, 10.1182/blood-2002-09-2801 Martinez-Garcia, 2011, The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells, Blood, 117, 211, 10.1182/blood-2010-07-298349 Kuo, 2011, NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming, Mol Cell, 44, 609, 10.1016/j.molcel.2011.08.042 Marango, 2008, The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor, Blood, 111, 3145, 10.1182/blood-2007-06-092122 Min, 2013, MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC, Leukemia, 27, 686, 10.1038/leu.2012.269 Ohguchi, 2018, The biological significance of histone modifiers in multiple myeloma: clinical applications, Blood Cancer J, 8, 83, 10.1038/s41408-018-0119-y Minami, 2014, Histone deacetylase 3 as a novel therapeutic target in multiple myeloma, Leukemia, 28, 680, 10.1038/leu.2013.231 Harada, 2017, HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications, Leukemia, 31, 2670, 10.1038/leu.2017.144 van de Donk, 2021, Multiple myeloma, Lancet, 397, 410, 10.1016/S0140-6736(21)00135-5 Raedler, 2016, Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma, Am Health Drug Benefits, 9, 84 Fagan, 2019, COMPASS ascending: emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer, Cancer Lett, 458, 56, 10.1016/j.canlet.2019.05.024 Wu, 2021, SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7, Cell Death Dis, 12, 439, 10.1038/s41419-021-03720-w Au, 2021, KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements, Leukemia, 35, 1012, 10.1038/s41375-020-1001-z Wang, 2020, Role of HDACs in normal and malignant hematopoiesis, Mol Cancer, 19, 5, 10.1186/s12943-019-1127-7 Harmeyer, 2017, JARID1 histone demethylases: emerging targets in cancer, Trends Cancer, 3, 713, 10.1016/j.trecan.2017.08.004 Saha, 2021, Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression, Biochim Biophys Acta Rev Cancer, 1875, 10.1016/j.bbcan.2020.188498 Strepkos, 2021, Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential, Cancer Res, 81, 525, 10.1158/0008-5472.CAN-20-2906 Hu, 2020, The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53, Cell Death Dis, 11, 328, 10.1038/s41419-020-2519-8 Wang, 2019, Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer, Am J Transl Res, 11, 1145 Hogg, 2020, Targeting the epigenetic regulation of antitumour immunity, Nat Rev Drug Discov, 19, 776, 10.1038/s41573-020-0077-5 Wang, 2017, Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines, Int J Oncol, 51, 1860, 10.3892/ijo.2017.4176 Brown, 2016, Targeting cancer using KAT inhibitors to mimic lethal knockouts, Biochem Soc Trans, 44, 979, 10.1042/BST20160081 Ye, 2019, Targeting epigenetic machinery: emerging novel allosteric inhibitors, Pharmacol Ther, 204, 10.1016/j.pharmthera.2019.107406 Ho, 2020, Thirty years of HDAC inhibitors: 2020 insight and hindsight, J Med Chem, 63, 12460, 10.1021/acs.jmedchem.0c00830 Marks, 2001, Histone deacetylases and cancer: causes and therapies, Nat Rev Cancer, 1, 194, 10.1038/35106079 Romero, 2019, HDAC inhibitors tested in phase III trial, Nat Rev Clin Oncol, 16, 465, 10.1038/s41571-019-0224-2 Manal, 2016, Inhibitors of histone deacetylase as antitumor agents: a critical review, Bioorg Chem, 67, 18, 10.1016/j.bioorg.2016.05.005 Singh, 2018, Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy, Nutrients, 10, 731, 10.3390/nu10060731 Gao, 2014, Rational design and validation of a Tip60 histone acetyltransferase inhibitor, Sci Rep, 4, 5372, 10.1038/srep05372 Coffey, 2001, The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all trans retinoic acid, Cancer Res, 61, 3591 Balliu, 2015, HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis, J Cell Mol Med, 19, 143, 10.1111/jcmm.12345 Eich, 2020, EZH2-targeted therapies in cancer: hype or a reality, Cancer Res, 80, 5449, 10.1158/0008-5472.CAN-20-2147 Cao, 2019, Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents, Eur J Med Chem, 179, 537, 10.1016/j.ejmech.2019.06.072 Biswas, 2018, Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy, Eur J Pharmacol, 837, 8, 10.1016/j.ejphar.2018.08.021 Li, 2018, Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression, Cell Death Dis, 9, 326, 10.1038/s41419-018-0347-x Nguyen, 2015, LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2, J Biol Chem, 290, 13641, 10.1074/jbc.M114.626861 Cao, 2020, DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation, Proc Natl Acad Sci U S A, 117, 27365, 10.1073/pnas.2001075117 Liu, 2014, DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy, PLoS One, 9, e98270, 10.1371/journal.pone.0098270 Kaniskan, 2018, Inhibitors of protein methyltransferases and demethylases, Chem Rev, 118, 989, 10.1021/acs.chemrev.6b00801 Cheng, 2004, Small molecule regulators of protein arginine methyltransferases, J Biol Chem, 279, 23892, 10.1074/jbc.M401853200 Kaniskan, 2015, A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3), Angew Chem Int Ed Engl, 54, 5166, 10.1002/anie.201412154 Nakayama, 2018, TP-064, a potene and selective small molecule inhibitor of PRMT4 for multiple myeloma, Oncotarget, 9, 18480, 10.18632/oncotarget.24883 Drew, 2017, Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma, Sci Rep, 7, 17993, 10.1038/s41598-017-18446-z Bonday, 2018, LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity, ACS Med Chem Lett, 9, 612, 10.1021/acsmedchemlett.8b00014 AbuHammad, 2019, Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma, Proc Natl Acad Sci U S A, 116, 17990, 10.1073/pnas.1901323116 Brehmer, 2021, Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity, Mol Cancer Ther, 20, 2317, 10.1158/1535-7163.MCT-21-0367 Jensen-Pergakes, 2022, SAM-Competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance, Mol Cancer Ther, 21, 3, 10.1158/1535-7163.MCT-21-0620 Mitchell, 2015, Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound, ACS Med Chem Lett, 6, 655, 10.1021/acsmedchemlett.5b00071 Dimitrova, 2015, Histone demethylases in chromatin biology and beyond, EMBO Rep, 16, 1620, 10.15252/embr.201541113 Gao, 2020, Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer, Nat Genet, 52, 1011, 10.1038/s41588-020-0681-7 Fang, 2019, LSD1/KDM1A inhibitors in clinical trials: advances and prospects, J Hematol Oncol, 12, 129, 10.1186/s13045-019-0811-9 He, 2022, Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present), Eur J Med Chem, 231, 10.1016/j.ejmech.2022.114143 Macedo-Silva, 2020, JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma, Cell Death Dis, 11, 1068, 10.1038/s41419-020-03279-y Kim, 2018, EHMT2 is a metastasis regulator in breast cancer, Biochem Biophys Res Commun, 496, 758, 10.1016/j.bbrc.2018.01.074 Vitkeviciene, 2018, Epigallocatechin-3-gallate and BIX-01294 have different impact on epigenetics and senescence modulation in acute and chronic myeloid leukemia cells, Eur J Pharmacol, 838, 32, 10.1016/j.ejphar.2018.09.005 Vedadi, 2011, A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells, Nat Chem Biol, 7, 566, 10.1038/nchembio.599 Sweis, 2014, Discovery and development of potent and selective inhibitors of histone methyltransferase g9a, ACS Med Chem Lett, 5, 205, 10.1021/ml400496h Yuan, 2012, A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma, ACS Chem Biol, 7, 1152, 10.1021/cb300139y Li, 2017, Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease, J Clin Investig, 127, 2751, 10.1172/JCI90921 Knutson, 2012, A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells, Nat Chem Biol, 8, 890, 10.1038/nchembio.1084 Konze, 2013, An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1, ACS Chem Biol, 8, 1324, 10.1021/cb400133j Verma, 2012, Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2, ACS Med Chem Lett, 3, 1091, 10.1021/ml3003346 Qi, 2012, Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation, Proc Natl Acad Sci U S A, 109, 21360, 10.1073/pnas.1210371110 Hayden, 2011, S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition, Breast Cancer Res Treat, 127, 109, 10.1007/s10549-010-0982-0 Zhang, 2021, PRMT4 inhibitor TP-064 impacts both inflammatory and metabolic processes without changing the susceptibility for early atherosclerotic lesions in male apolipoprotein E knockout mice, Atherosclerosis, 338, 23, 10.1016/j.atherosclerosis.2021.11.001 Prusevich, 2014, A selective phenelzine analogue inhibitor of histone demethylase LSD1, ACS Chem Biol, 9, 1284, 10.1021/cb500018s Zhu, 2012, Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells, Amino Acids, 42, 887, 10.1007/s00726-011-1004-1 Willmann, 2012, Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor, Int J Cancer, 131, 2704, 10.1002/ijc.27555 Ogasawara, 2013, Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism, Angew Chem Int Ed Engl, 52, 8620, 10.1002/anie.201303999 Wang, 2013, A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth, Nat Commun, 4, 2035, 10.1038/ncomms3035 Hopkinson, 2013, 5-carboxy-8-hydroxyquinoline is a broad spectrum 2-oxoglutarate oxygenase inhibitor which causes iron translocation, Chem Sci, 4, 3110, 10.1039/c3sc51122g Tang, 2017, Aurora kinases: novel therapy targets in cancers, Oncotarget, 8, 23937, 10.18632/oncotarget.14893 Yu, 2021, Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation, Eur J Med Chem, 214, 10.1016/j.ejmech.2021.113248 Ammazzalorso, 2021, Development of CDK4/6 inhibitors: a five years update, Molecules, 26, 1488, 10.3390/molecules26051488 Wu, 2021, PIM kinases in multiple myeloma, Cancers (Basel), 13, 4304, 10.3390/cancers13174304 Szydłowski, 2021, Inhibition of PIM kinases in DLBCL targets MYC transcriptional program and augments the efficacy of anti-CD20 antibodies, Cancer Res, 81, 6029, 10.1158/0008-5472.CAN-21-1023 2017, AACR project GENIE: powering precision medicine through an international consortium, Cancer Discov, 7, 818, 10.1158/2159-8290.CD-17-0151 Wehde, 2018, Janus kinase 1 plays a critical role in mammary cancer progression, Cell Rep, 25, 2192, 10.1016/j.celrep.2018.10.063 Beatty, 2019, A phase Ib/II study of the JAK1 inhibitor, itacitinib, plus nab-paclitaxel and gemcitabine in advanced solid tumors, Oncologist, 24, 14, 10.1634/theoncologist.2017-0665 Young, 2019, The role of ubiquitin-specific peptidases in cancer progression, J Biomed Sci, 26, 42, 10.1186/s12929-019-0522-0 Gutierrez-Diaz, 2020, Deubiquitinases: pro-oncogenic activity and therapeutic targeting in blood malignancies, Trends Immunol, 41, 327, 10.1016/j.it.2020.02.004 Huarte, 2020, Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy, Clin Cancer Res, 26, 6299, 10.1158/1078-0432.CCR-20-1739 Liang, 2014, A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses, Nat Chem Biol, 10, 298, 10.1038/nchembio.1455 Davis, 2016, Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models, J Biol Chem, 291, 24628, 10.1074/jbc.M116.738567 Ma, 2020, Inhibition of USP14 and UCH37 deubiquitinating activity by b-AP15 as a potential therapy for tumors with p53 deficiency, Signal Transduct Target Ther, 5, 30, 10.1038/s41392-020-0143-9 He, 2020, The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival, J Biol Chem, 295, 2084, 10.1074/jbc.RA119.010724 Chao, 2014, Synergistic loss of prostate cancer cell viability by co-inhibition of HDAC and PARP, Mol Cancer Res, 12, 1755, 10.1158/1541-7786.MCR-14-0173 Duan, 2020, EZH2: a novel target for cancer treatment, J Hematol Oncol, 13, 104, 10.1186/s13045-020-00937-8 Lu, 2020, Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy, Mol Cancer, 19, 79, 10.1186/s12943-020-01197-3 Hoy, 2020, Tazemetostat: first approval, Drugs, 80, 513, 10.1007/s40265-020-01288-x Sarno, 2021, Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside, Clin Epigenetics, 13, 10.1186/s13148-021-01047-z Silverman, 2020, Molecular networks in network medicine: development and applications, Wiley Interdiscip Rev Syst Biol Med, 12, e1489, 10.1002/wsbm.1489 Kurnat-Thoma, 2020, Recent advances in systems and network medicine: meeting report from the first international conference in systems and network medicine, Syst Med, 3, 22, 10.1089/sysm.2020.0001 Boehm, 2022, Harnessing multimodal data integration to advance precision oncology, Nat Rev Cancer, 22, 114, 10.1038/s41568-021-00408-3